Méhtestrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 5
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

1290 intézményből 24, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 321 301 EUR· until 2030. máj.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours (STP938)

  Step Pharma· Paris, Franciaország· EU contribution 2 499 991 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

2 of 2 running projects, newest first. Listed amounts together: 2,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  PRO1107 in Patients With Advanced Solid Tumors

  NCT06171789· Genmab· Frissítve: 2026. okt. 29.

  “Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

  NCT05833321· Centre Hospitalier Metropole Savoie· Frissítve: 2026. okt. 8.

  “recruitement failure”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

  NCT05827614· Boundless Bio, Inc.· Frissítve: 2026. aug. 19.

  “Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

  NCT05572684· NextCure, Inc.· Frissítve: 2026. aug. 13.

  “Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  GEN1047 for Solid Tumors - First in Human (FIH) Trial

  NCT05180474· Genmab· Frissítve: 2026. júl. 23.

  “The Sponsor has made a strategic decision to stop the development of GEN1047.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

  NCT05714553· NuCana plc· Frissítve: 2026. júl. 23.

  “The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

  NCT04527900· University of Maryland, Baltimore· Frissítve: 2026. júl. 8.

  “SOC changed and low enrollment”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

  NCT05316467· Xiaojun Chen· Frissítve: 2026. jún. 4.

  “no enough enrolled patients”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Frissítve: 2026. jún. 4.

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

  NCT05523440· University of Oklahoma· Frissítve: 2026. jún. 3.

  “Funding issue”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  NCT05564377· National Cancer Institute (NCI)· Forrás

• Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  NCT05950464· National Cancer Institute (NCI)· Forrás

• Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

  NCT01174121· National Cancer Institute (NCI)· Forrás

• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

  NCT05554328· National Cancer Institute (NCI)· Forrás

• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

  NCT04704661· National Cancer Institute (NCI)· Forrás

• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

  NCT05538897· National Cancer Institute (NCI)· Forrás

• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

  NCT05256225· National Cancer Institute (NCI)· Forrás

• Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  NCT05112601· National Cancer Institute (NCI)· Forrás

• Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

  NCT04491942· National Cancer Institute (NCI)· Forrás

• A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)

  2025-524160-38-00· Merck Sharp & Dohme LLC· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 8
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• Illustrating the "Quiet Genome" Concept of SMARCA4 -Deficient Uterine Sarcoma Via Whole-Exome Sequencing: A Highly Aggressive Case in a Young Woman.

  Int J Gynecol Pathol, 2026. máj.

• Genomic and Transcriptomic Analysis of High-Grade Endometrial Carcinoma Reveals Biological Heterogeneity and Molecular Classification Challenges.

  Cancer Res Commun, 2026. ápr.

• Comparison of clinical, pathological and genomic characteristics between Lynch and non-Lynch patients with MMRd endometrial carcinoma.

  BMC Cancer, 2026. márc.

• Integrated mutational landscape analysis of endometrial stromal sarcoma.

  Proc Natl Acad Sci U S A, 2026. jan.

• ERBB2 amplification is a late event in the pathogenesis of high-grade endometrial carcinomas with heterogeneous HER2 expression.

  J Pathol, 2026. jan.

• ATR&RNASEL germline variants: novel findings in a case of familial cancer.

  Mol Genet Genomics, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.